Protagonist Therapeutics, Inc. (NASDAQ:PTGX) | WebDisclosure

Basculer en Français

8609	Companies
141447	Keywords
77324	Articles
75565	Press releases

Headlines Articles Press releases Protagonist Therapeutics, Inc.

Home
Companies
Protagonist Therapeutics, Inc.

BRIEF

published on 03/08/2025 at 15:20, 1 month 2 days ago

Protagonist Therapeutics dévoile des résultats prometteurs pour l'icotrokinra dans le traitement du psoriasis

Essais Cliniques Thérapeutique Protagoniste Icotrokinra Psoriasis En Plaques Efficacité Du Traitement
PRESS RELEASE

published on 03/08/2025 at 15:15, 1 month 2 days ago

Icotrokinra Clinical Study Results Demonstrate Its Potential to Shift Treatment Paradigm and Set a New Standard for Treatment in Plaque Psoriasis
Protagonist Therapeutics announces new data on icotrokinra in Phase 3 studies for moderate-to-severe plaque psoriasis. Launching first head-to-head study vs. ustekinumab

Phase 3 Protagonist Therapeutics Plaque Psoriasis Icotrokinra Head-to-head Study
BRIEF

published on 02/21/2025 at 13:05, 1 month 17 days ago

Protagonist Therapeutics Announces 2024 Financial Results and Corporate Progress

Protagonist Therapeutics Financial Results 2024 Icotrokinra Milestone Rusfertide VERIFY Trial Takeda Collaboration
BRIEF

published on 02/21/2025 at 13:05, 1 month 17 days ago

Protagonist Therapeutics annonce ses résultats financiers et les progrès de l'entreprise pour 2024

Résultats Financiers 2024 Thérapeutique Protagoniste Étape Importante De L'Icotrokinra Essai Rusfertide VERIFY Collaboration Avec Takeda
PRESS RELEASE

published on 02/21/2025 at 13:00, 1 month 17 days ago

Protagonist Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
Protagonist Therapeutics reports $165.0 million milestone achieved in Q4 2024 and key milestones for 2025 including icotrokinra and rusfertide trial results. Financial results for Q4 2024 revealed

Financial Results Clinical Trial Milestone Protagonist Therapeutics Rusfertide
BRIEF

published on 01/30/2025 at 00:20, 2 months 11 days ago

Protagonist Therapeutics Announces Investor Event Focused on Polycythemia Vera and Rusfertide

Clinical Trials Investor Event Protagonist Therapeutics Rusfertide Polycythemia Vera
BRIEF

published on 01/30/2025 at 00:20, 2 months 11 days ago

Protagonist Therapeutics annonce un événement destiné aux investisseurs axé sur la polycythémie vraie et le rusfertide

Essais Cliniques Rusfertide Thérapeutique Protagoniste Événement Pour Les Investisseurs Polycythémie Vraie
PRESS RELEASE

published on 01/30/2025 at 00:15, 2 months 11 days ago

Protagonist to Host Investor Event with KOL Insights on Polycythemia Vera (PV) and the Hepcidin Mimetic Rusfertide in New York on February 6, 2025
Protagonist Therapeutics to host investor event discussing Rusfertide Phase 3 VERIFY study design and Phase 2 data with key opinion leaders. Company also to provide commercial opportunity snapshot. Live Q&A session and lunch included

Investor Event Protagonist Therapeutics Rusfertide Phase 3 VERIFY Study Commercial Opportunity
BRIEF

published on 01/06/2025 at 22:10, 3 months 3 days ago

Protagonist Therapeutics annonce des primes d'encouragement à un nouveau dirigeant

Nasdaq Thérapeutique Protagoniste Options Sur Actions Primes D'encouragement Nouveau Comité Exécutif
BRIEF

published on 01/06/2025 at 22:10, 3 months 3 days ago

Protagonist Therapeutics Announces Inducement Awards to New Executive

Stock Options Nasdaq Protagonist Therapeutics Inducement Awards New Executive

Accesswire

Published on 04/10/2025 at 15:15, 48 minutes ago

ReelTime’s Reel Intelligence "RI" Outperforms AI While Requiring a Fraction of The Resources
Published on 04/10/2025 at 15:00, 1 hour 3 minutes ago

Route1 Signs Significant New Orders with Major Cities in the Southwestern United States and Announces Key Corporate Updates Including Its Acquisition Growth Strategy
Published on 04/10/2025 at 15:00, 1 hour 3 minutes ago

Inspire Veterinary Partners Announces Attendance at Upcoming Investor Events
Published on 04/10/2025 at 15:00, 1 hour 3 minutes ago

Xebra Brands Launches National RFP to Establish Cannabis Cultivation Partnerships Across Mexico
Published on 04/10/2025 at 14:30, 1 hour 33 minutes ago

CCL to Hold Live Webcast Call to Discuss 2025 First Quarter Results, Thursday, May 8, 2025, at 7:30 a.m. ET

View all ACCESSWIRE

EQS Group

Published on 04/10/2025 at 15:40, 22 minutes ago

Financing commitment: American West secures long-term future of the Storm copper project!
Published on 04/10/2025 at 15:30, 32 minutes ago

Siegfried shareholders approve all proposals at Annual General Meeting 2025
Published on 04/10/2025 at 15:00, 1 hour 2 minutes ago

Eckert & Ziegler: US Consul Visits Radiopharmaceutical Production in Braunschweig
Published on 04/10/2025 at 13:50, 2 hours 12 minutes ago

Viromed Medical AG: Exclusive distribution partnership with AMAMUS Vet for the cold plasma medical device ViroCAP® VET for veterinary use
Published on 04/10/2025 at 13:12, 2 hours 50 minutes ago

CureVac Announces Financial Results for the Fourth Quarter and Full-Year 2024 and Provides Business Update

Les Echos

Published on 04/09/2025 at 18:59, 21 hours 3 minutes ago

Description of the 2025-2026 Share Buyback Program
Published on 04/09/2025 at 18:59, 21 hours 3 minutes ago

Descriptif du programme de rachat d'actions 2025-2026
Published on 04/09/2025 at 18:57, 21 hours 5 minutes ago

Minutes of the Combined General Meeting held on April 9, 2025
Published on 04/09/2025 at 18:57, 21 hours 5 minutes ago

Compte-rendu de l'Assemblée Générale Mixte du 9 avril 2025
Published on 04/09/2025 at 17:45, 22 hours 18 minutes ago

COGELEC : Résultats annuels 2024 et Chiffre d’affaires du 1 er trimestre 2025.

View all LES ECHOS COMFI WIRE